Two-drug combinations targeting MAPK and PI3K/Akt signaling pathways in parallel impart synergistic inhibition of tumor growth and metastasis in mouse models of MM with Ras/MAPK and PI3K/AKT/mTOR activation (29, 44). The gene discussed is AKT1; the disease is neoplasm.